Cozad Asset Management Inc. Increases Holdings in Novo Nordisk A/S (NYSE:NVO)

Cozad Asset Management Inc. grew its holdings in Novo Nordisk A/S (NYSE:NVO) by 14.5% during the third quarter, HoldingsChannel reports. The fund owned 23,901 shares of the company’s stock after purchasing an additional 3,020 shares during the period. Cozad Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $2,846,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in NVO. GQG Partners LLC lifted its position in shares of Novo Nordisk A/S by 654.6% during the 1st quarter. GQG Partners LLC now owns 3,633,064 shares of the company’s stock worth $466,485,000 after buying an additional 3,151,584 shares during the last quarter. International Assets Investment Management LLC lifted its position in Novo Nordisk A/S by 10,608.4% in the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after acquiring an additional 1,796,635 shares during the last quarter. DSM Capital Partners LLC boosted its stake in Novo Nordisk A/S by 257,816.0% in the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after acquiring an additional 1,593,303 shares in the last quarter. Acadian Asset Management LLC boosted its stake in Novo Nordisk A/S by 1,300.8% in the first quarter. Acadian Asset Management LLC now owns 1,244,128 shares of the company’s stock valued at $159,703,000 after acquiring an additional 1,155,313 shares in the last quarter. Finally, Mediolanum International Funds Ltd purchased a new position in shares of Novo Nordisk A/S during the third quarter worth about $98,765,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on NVO shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday. BMO Capital Markets reduced their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. Finally, StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Novo Nordisk A/S currently has an average rating of “Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Stock Down 4.3 %

Novo Nordisk A/S stock opened at $105.35 on Thursday. The stock has a market capitalization of $472.76 billion, a price-to-earnings ratio of 36.08, a PEG ratio of 1.43 and a beta of 0.42. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.46. The stock has a 50 day moving average of $122.65 and a two-hundred day moving average of $130.59. Novo Nordisk A/S has a twelve month low of $94.73 and a twelve month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.65 earnings per share for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). The firm had revenue of $9.82 billion during the quarter, compared to analysts’ expectations of $9.91 billion. Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. As a group, research analysts expect that Novo Nordisk A/S will post 3.01 earnings per share for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.